BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
See today's BioWorld
Home
» Alexion's Kanuma A-OK with FDA in first LAL-D nod
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Alexion's Kanuma A-OK with FDA in first LAL-D nod
Dec. 9, 2015
By
Marie Powers
No Comments
The pick-up of Synageva Biopharma Corp. provided an early payback for Alexion Pharmaceuticals Inc., which saw the FDA green-light Kanuma (sebelipase alfa) as the first approved U.S. therapy to treat patients with lysosomal acid lipase deficiency.
BioWorld